Join BioAtla for a virtual R&D Day featuring Drs. Edwin Yau, MD, PhD (Roswell Park Comprehensive Cancer Center), Omid Hamid, MD (The Angeles Clinic and Research Institute), and Ankit Mangla, MD (University Hospitals Seidman Cancer Center) who will review BioAtla’s Phase 2 clinical trial results for mecbotamab vedotin (CAB-AXL-ADC) in non-small cell lung cancer (NSCLC) and evalstotug (CAB-CTLA-4 antibody) in treatment-refractory solid tumors.

A live question and answer session will follow the formal presentation.